1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD
X. Le(The University of Texas MD Anderson Cancer Center), Sarah B. Goldberg(Yale University), B.C. Cho(Yonsei University), L. Bonanno(Istituto Oncologico Veneto), Tarje Onsøien Halvorsen(St Olav's University Hospital), H.A. Yu(Memorial Sloan Kettering Cancer Center), Yu Jung Kim(Seoul National University Bundang Hospital), Alessandro Morabito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), L. Hendriks(Maastricht University Medical Centre), Adrianus J. de Langen(The Netherlands Cancer Institute), Kristen A. Marrone(Johns Hopkins University), John M. Lehman(AstraZeneca (Netherlands)), Zofia Piotrowska(Global Cancer Institute), Jonathan W. Riess(University of California Davis Medical Center), P.G. Fraenkel(AstraZeneca (South Korea)), J.W. Goldman(University of California, Los Angeles), Isamu Okamoto(Kyushu University), Peter J. Smith, Helen Ambrose(AstraZeneca (United Kingdom)), O.T. Brustugun(Drammen Hospital)
Cited by 22
Related Papers
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k